Vaxart Inc (VXRT)
0.5724
-0.18
(-23.67%)
USD |
NASDAQ |
Jun 14, 16:00
0.623
+0.05
(+8.84%)
After-Hours: 20:00
Vaxart Research and Development Expense (TTM): 67.53M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 67.53M |
| December 31, 2023 | 68.14M |
| September 30, 2023 | 73.90M |
| June 30, 2023 | 81.36M |
| March 31, 2023 | 82.47M |
| December 31, 2022 | 81.05M |
| September 30, 2022 | 76.12M |
| June 30, 2022 | 66.07M |
| March 31, 2022 | 56.88M |
| December 31, 2021 | 48.75M |
| September 30, 2021 | 41.81M |
| June 30, 2021 | 34.02M |
| March 31, 2021 | 28.39M |
| December 31, 2020 | 19.86M |
| September 30, 2020 | 14.56M |
| June 30, 2020 | 13.66M |
| March 31, 2020 | 12.25M |
| December 31, 2019 | 14.54M |
| September 30, 2019 | 15.72M |
| June 30, 2019 | 16.39M |
| March 31, 2019 | 17.70M |
| December 31, 2018 | 17.28M |
| September 30, 2018 | 15.30M |
| June 30, 2018 | 13.72M |
| March 31, 2018 | 12.41M |
| Date | Value |
|---|---|
| December 31, 2017 | 15.80M |
| September 30, 2017 | 23.50M |
| June 30, 2017 | 28.30M |
| March 31, 2017 | 30.50M |
| December 31, 2016 | 32.20M |
| September 30, 2016 | 28.30M |
| June 30, 2016 | 26.20M |
| March 31, 2016 | 25.60M |
| December 31, 2015 | 21.90M |
| September 30, 2015 | 20.40M |
| June 30, 2015 | 19.80M |
| March 31, 2015 | 20.70M |
| December 31, 2014 | 20.00M |
| September 30, 2014 | 19.40M |
| June 30, 2014 | 17.50M |
| March 31, 2014 | 17.64M |
| December 31, 2013 | 18.48M |
| September 30, 2013 | 13.90M |
| June 30, 2013 | 14.04M |
| March 31, 2013 | 9.029M |
| December 31, 2012 | 5.611M |
| September 30, 2012 | 7.579M |
| June 30, 2012 | 8.822M |
| March 31, 2012 | 13.95M |
| December 31, 2011 | 17.76M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
12.25M
Minimum
Mar 2020
82.47M
Maximum
Mar 2023
45.67M
Average
45.28M
Median
Research and Development Expense (TTM) Benchmarks
| Novavax Inc | 583.08M |
| Inovio Pharmaceuticals Inc | 77.41M |
| Stereotaxis Inc | 9.77M |
| Arcturus Therapeutics Holdings Inc | 193.94M |
| Capricor Therapeutics Inc | 39.89M |